The UK's biggest drug maker, GlaxoSmithKline, said yesterday that it is axing as many as 850 jobs in its British and US research and development units. The cuts, intended to improve productivity, are in addition to the 350 loses announced in June.
"Following a recent review of business operations, we have started consultation on proposals which could impact 850 roles in the UK and the US. It has been difficult to arrive at these proposals, but we believe these changes are necessary as part of GSK's longer-term strategy" a spokesperson said.
GSK is undertaking a review of its entire business, which was first announced at the end of 2007. The group hopes to save £700m by 2010, including £350m by the end of next year.
The spokesperson said that it is unclear at this stage how many jobs would be lost in the UK.